The Lynx Group

Myelodysplastic Syndromes

Understanding the Current Classification Criterion and Prognostic Models for the Myelodysplastic Syndromes and Dysplastic Cytopenias of Undetermined Significance as a Paradigm for Personalized Medicine

Myelodysplastic syndromes (MDS) define a group of hematologic disorders whose pathologic findings have been well defined.1 Controversy exists, however, in the reproducibility of the various subtypes. The 4th edition of the World Health Organization’s WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues was last published in 2008.2,3 The [ Read More ]

Personalized Therapy in the Management of Myelodysplastic Syndromes (MDS)

At the 2012 conference of the Global Biomarkers Consortium, which took place March 9-11, 2012, in Orlando, Florida, Gautam Borthakur, MD, from The University of Texas MD Anderson Cancer Center in Houston, Texas, discussed the use of personalized therapy in the management of MDS. The myelodysplastic syndromes (MDS) are a [ Read More ]

Sign me up!